On April 27, 2026, Biomea Fusion, Inc. reported positive results from its Phase 2 trial of icovamenib for type 1 diabetes, showing a 52% increase in mean C-peptide area under the curve after 12 weeks of treatment. The therapy demonstrated sustained effects, indicating potential for future studies.